val158met is not associated with Aβ-amyloid and ε4 related cognitive decline in cognitively normal older adults.

IBRO Rep 2019 Jun 2;6:147-152. Epub 2019 May 2.

Collaborative Genomics Group, Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup 6027, Western Australia, Australia.

The non-synonymous single nucleotide polymorphism (SNP), Val158Met within the Catechol--methyltransferase () gene has been associated with altered levels of cognition and memory performance in cognitively normal adults. This study aimed to investigate the independent and interactional effects of Val158Met on cognitive performance. In particular, it was hypothesised that Val158Met would modify the effect of neocortical Aβ-amyloid (Aβ) accumulation and carriage of the apolipoprotein E ( ε4 allele on cognition in preclinical Alzheimer's disease (AD). In 598 cognitively normal older adults with known neocortical Aβ levels, linear mixed modelling revealed no significant independent or interactional associations between Val158Met and cognitive decline. These findings do not support previous associations between Val158Met and cognitive performance and suggest this variant does not influence Aβ-amyloid or ε4 driven cognitive decline in a well characterised cohort of cognitively normal older adults.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ibror.2019.05.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6506436PMC
June 2019

Publication Analysis

Top Keywords

cognitively normal
16
normal older
12
older adults
12
val158met cognitive
12
cognitive decline
12
independent interactional
8
aβ-amyloid ε4
8
associations val158met
8
cognitive performance
8
val158met
6
cognitive
5
apolipoprotein ε4
4
carriage apolipoprotein
4
disease 598
4
cognition preclinical
4
preclinical alzheimer's
4
allele cognition
4
alzheimer's disease
4
ε4 allele
4
neocortical aβ-amyloid
4

Similar Publications